Overview

A Study of Nasal Glucagon in Participants With Type 1 Diabetes Mellitus

Status:
Completed
Trial end date:
2018-01-13
Target enrollment:
Participant gender:
Summary
The purpose of this study is to compare a needle-free treatment of hypoglycemia with nasal glucagon (study drug) to a marketed glucagon administered by the intramuscular (IM) route, in participants with type 1 diabetes mellitus (T1DM).
Phase:
Phase 1
Details
Lead Sponsor:
Eli Lilly and Company
Treatments:
Glucagon
Glucagon-Like Peptide 1
Pharmaceutical Solutions